https://cartcellschina.com/ https://cartcellschina.com/car-t-moving-earlier-in-multiple-myeloma-a-new-treatment-landscape/ 2026-08-27T17:25:54+08:00 https://cartcellschina.com/nccn-2026-acute-lymphoblastic-leukemia-guidelines-car-t-moves-into-the-core-treatment-landscape-for-b-all/ 2026-08-14T15:49:30+08:00 https://cartcellschina.com/satri-cel-car-t-therapy-shows-long-term-survival-benefits-in-advanced-gastric-cancer-with-peritoneal-metastasis/ 2026-08-03T19:38:08+08:00 https://cartcellschina.com/cldn18-2-car-t-therapy-achieves-48-month-disease-control-and-conversion-surgery-in-advanced-gastric-cancer-with-peritoneal-metastasis/ 2026-08-05T10:00:00+08:00 https://cartcellschina.com/carteyva-car-t-achieves-durable-complete-remission-in-high-risk-pod24-follicular-lymphoma/ 2026-07-27T23:56:23+08:00 https://cartcellschina.com/why-people-travel-abroad-to-china-for-stomach-cancer-treatment/ 2026-07-25T13:47:12+08:00 https://cartcellschina.com/from-remission-to-potential-cure-long-term-car-t-data-redefines-lymphoma-treatment-in-china/ 2026-07-15T07:43:30+08:00 https://cartcellschina.com/eque-cel-fucaso-enables-durable-remission-in-a-multiple-myeloma-patient-relapsed-after-two-transplants/ 2026-07-09T23:20:42+08:00 https://cartcellschina.com/satri-cel-demonstrates-durable-long-term-benefit-in-advanced-gastric-cancer-asco-2026-update/ 2026-07-08T10:00:00+08:00 https://cartcellschina.com/2026-eha-bcmaxgprc5d-car-t-therapy-ol-101-shows-remarkable-efficacy-in-relapsed-refractory-multiple-myeloma/ 2026-07-03T10:00:00+08:00 https://cartcellschina.com/case-report-asct-combined-with-equecabtagene-autoleucel-bcma-car-t-cell-therapy-achieves-sustained-scr-with-mrd-negativity-in-ultra-high-risk-multiple-myeloma/ 2026-07-01T10:00:00+08:00 https://cartcellschina.com/study-in-china-highlights-car-t-cell-therapy-success-in-colorectal-cancer/ 2026-06-29T15:48:08+08:00 https://cartcellschina.com/three-emerging-immunotherapies-for-multiple-myeloma-car-t-adcs-and-bispecific-antibodies/ 2026-06-24T23:45:22+08:00 https://cartcellschina.com/satri-cel-ct041-kaileimei-receives-nmpa-approval-the-worlds-first-car-t-cell-therapy-for-solid-tumors/ 2026-06-24T23:30:45+08:00 https://cartcellschina.com/cldn18-2-a-new-beacon-of-hope-in-pancreatic-cancer-treatment/ 2026-06-21T20:02:24+08:00 https://cartcellschina.com/long-term-follow-up-study-identifies-ki-67-as-a-negative-prognostic-marker-for-cd19-car-t-therapy-in-r-r-b-cell-non-hodgkin-lymphoma/ 2026-06-17T22:12:02+08:00 https://cartcellschina.com/chinas-first-yescarta-is-the-first-approved-car-t-cell-therapy-in-the-country/ 2026-06-17T20:59:17+08:00 https://cartcellschina.com/carteyva-relmacabtagene-autoleucel-approved-in-china/ 2026-06-17T20:59:10+08:00 https://cartcellschina.com/dr-zhu-jun-carteyva-car-t-cell-therapy-is-a-milestone-in-chinas-fight-against-cancer/ 2026-06-17T20:59:02+08:00 https://cartcellschina.com/better-safety-less-and-milder-side-effects-carteyva-offers-deep-remission-and-hope-for-a-cure/ 2026-06-17T20:58:51+08:00 https://cartcellschina.com/carteyva-relmacabtagene-autoleucel-offers-long-term-benefits-with-a-single-infusion/ 2026-06-17T20:58:41+08:00 https://cartcellschina.com/car-t-cell-therapy-in-china-carteyva-brings-new-hope-to-lymphoma-patients/ 2026-06-17T20:58:31+08:00 https://cartcellschina.com/nmpa-approval-of-carteyva-in-patients-with-relapsed-or-refractory-follicular-lymphoma/ 2026-06-17T20:58:14+08:00 https://cartcellschina.com/fucaso-approved-in-china-the-worlds-first-fully-human-bcma-car-t-cell-therapy-for-r-r-multiple-myeloma/ 2026-06-17T20:58:05+08:00 https://cartcellschina.com/fosun-kites-car-t-second-line-indication-approved-opening-a-new-chapter-in-lymphoma-treatment/ 2026-06-17T20:57:55+08:00 https://cartcellschina.com/yorwida-cnct19-chinas-first-cd19-car-t-therapy-for-adult-b-all/ 2026-06-17T20:57:45+08:00 https://cartcellschina.com/nmpa-approves-zevor-cel-for-relapsed-or-refractory-multiple-myeloma/ 2026-06-17T20:57:31+08:00 https://cartcellschina.com/yescarta-is-now-available-in-macao/ 2026-06-17T20:57:20+08:00 https://cartcellschina.com/relma-cel-achieves-66-7-4-year-survival-in-r-r-lbcl-asco-2024-reports/ 2026-06-17T20:57:11+08:00 https://cartcellschina.com/real-world-study-confirms-efficacy-and-safety-of-relma-cel-in-relapsed-refractory-cns-lymphoma/ 2026-06-17T20:57:02+08:00 https://cartcellschina.com/carvykti-approved-in-china-for-relapsed-or-refractory-multiple-myeloma/ 2026-06-17T20:56:51+08:00 https://cartcellschina.com/new-indication-approved-to-carteyva-mantle-cell-lymphoma-mcl-is-now-treatable-in-china-with-car-t-cell-therapy/ 2026-06-17T20:56:42+08:00 https://cartcellschina.com/latest-clinical-data-revealed-that-carvykti-has-significantly-extended-overall-survival-os-in-second-line-multiple-myeloma-patients/ 2026-06-17T20:56:31+08:00 https://cartcellschina.com/car-t-therapy-a-new-approach-to-treating-large-b-cell-lymphoma/ 2026-06-17T20:56:17+08:00 https://cartcellschina.com/blood-advances-inaticabtagene-autoleucel-cnct19-in-adult-relapsed-or-refractory-b-cell-acute-lymphoblastic-leukemia/ 2026-06-17T20:56:07+08:00 https://cartcellschina.com/car-t-therapy-equecabtagene-autoleucel-fucaso-demonstrates-efficacy-and-safety-in-heavily-pretreated-multiple-myeloma-patients/ 2026-06-17T20:55:54+08:00 https://cartcellschina.com/carteyva-granted-breakthrough-therapy-designation-for-second-line-r-r-lbcl/ 2026-06-17T20:55:43+08:00 https://cartcellschina.com/new-car-t-therapy-targeting-gprc5d-shows-promise-for-relapsed-refractory-multiple-myeloma/ 2026-06-17T20:55:32+08:00 https://cartcellschina.com/worlds-first-chinas-stomach-cancer-car-t-therapy-nears-approval-with-96-success/ 2026-06-17T20:55:20+08:00 https://cartcellschina.com/immunotherapy-breakthroughs-reshape-the-treatment-landscape-for-multiple-myeloma/ 2026-06-17T20:55:10+08:00 https://cartcellschina.com/a-new-hope-for-multiple-myeloma-understanding-bcma-car-t-therapy/ 2026-06-17T20:54:50+08:00 https://cartcellschina.com/carteyva-a-promising-car-t-therapy-for-follicular-lymphoma/ 2026-06-17T20:54:40+08:00 https://cartcellschina.com/chinese-expert-consensus-2025-t-cell-immunotherapy-in-treatment-of-aggressive-b-cell-lymphoma/ 2026-06-17T20:54:10+08:00 https://cartcellschina.com/breakthrough-gprc5d-car-t-therapy-ct071-shows-promising-results-for-refractory-multiple-myeloma/ 2026-06-17T20:53:18+08:00 https://cartcellschina.com/updated-long-term-follow-up-data-for-zevorcabtagene-autoleucel-zevor-cel-presented-at-ims-2025/ 2026-06-17T20:52:34+08:00 https://cartcellschina.com/ims-2025-professor-qiu-lugui-eque-cel-demonstrates-favorable-safety-and-efficacy-in-heavily-pretreated-r-r-mm-patients/ 2026-06-17T20:52:21+08:00 https://cartcellschina.com/car-t-cell-therapy-and-transplantation-evolving-strategies-for-deep-remission/ 2026-06-17T20:52:03+08:00 https://cartcellschina.com/gastric-cancer-66-percent-tumor-reduction-and-durable-60-week-complete-remission/ 2026-06-17T20:51:31+08:00 https://cartcellschina.com/first-solid-tumor-car-t-therapy-enters-csco-gastric-cancer-guidelines-2026-a-defining-moment-for-clinical-practice/ 2026-06-17T20:51:24+08:00 https://cartcellschina.com/2026-china-car-t-breakthroughs-revolutionary-progress-in-gastric-cancer-and-solid-tumors/ 2026-06-17T20:51:16+08:00 https://cartcellschina.com/what-is-a-solid-tumor-new-treatment-options-and-the-rise-of-car-t-therapy-for-solid-tumors-in-china/ 2026-06-17T20:51:09+08:00 https://cartcellschina.com/alternative-car-t-cell-therapy-option-for-multiple-myeloma-you-should-know/ 2026-06-17T20:50:58+08:00 https://cartcellschina.com/cd7-car-t-therapy-for-relapsed-refractory-t-cell-lymphoma-a-single-arm-open-label-phase-i-study/ 2026-06-17T20:50:34+08:00 https://cartcellschina.com/inaticabtagene-autoleucel-received-approval-for-r-r-lymphoma/ 2026-06-17T20:50:17+08:00 https://cartcellschina.com/puzolcabtagene-autoleucel-approved-in-china-for-pediatric-b-cell-acute-lymphoblastic-leukemia/ 2026-06-17T20:49:53+08:00 https://cartcellschina.com/encouraging-data-from-universal-cd19-cd20-car-t-therapy-in-relapsed-refractory-lymphoma/ 2026-06-17T20:49:43+08:00 https://cartcellschina.com/promising-results-from-universal-bcma-car-t-therapy-in-relapsed-refractory-multiple-myeloma/ 2026-06-17T20:49:30+08:00 https://cartcellschina.com/second-line-car-t-therapy-for-lbcl-shows-lower-hematologic-toxicity-and-improved-safety-in-real-world-study/ 2026-06-17T18:43:55+08:00 https://cartcellschina.com/what-cancers-can-be-treated-with-car-t-cell-therapy-2/ 2026-06-04T23:12:51+08:00 https://cartcellschina.com/study-insight-tumor-burden-reduction-may-be-key-to-improving-car-t-outcomes-in-lymphoma/ 2026-04-06T17:18:21+08:00 https://cartcellschina.com/efficacy-and-safety-of-inaticabtagene-autoleucel-for-b-all-in-china-insights-from-a-real-world-study/ 2026-04-05T07:20:52+08:00 https://cartcellschina.com/inati-cel-yorwida-demonstrates-promising-efficacy-and-safety-in-adult-b-all-patients-with-post-transplant-relapse/ 2026-04-05T07:16:55+08:00 https://cartcellschina.com/cd19-car-t-therapy-offers-long-term-survival-hope-for-b-all-patients-relapsing-after-allo-hsct/ 2026-03-14T23:00:33+08:00 https://cartcellschina.com/bcma-car-t-therapy-in-china-shows-breakthrough-potential-in-multiple-sclerosis/ 2026-03-14T22:41:21+08:00 https://cartcellschina.com/carteyva-car-t-therapy-in-china-offers-a-new-strategy-for-relapsed-refractory-mantle-cell-lymphoma/ 2026-02-27T00:07:59+08:00 https://cartcellschina.com/dual-target-bcma-cd19-car-t-therapy-demonstrates-durable-remission-and-long-term-safety-in-systemic-lupus-erythematosus/ 2026-02-15T00:12:17+08:00 https://cartcellschina.com/cd19-cd20-dual-target-car-t-therapy-delivers-durable-responses-with-manageable-safety-in-relapsed-refractory-b-cell-lymphoma/ 2026-01-19T23:03:59+08:00 https://cartcellschina.com/annual-review-nmpa-approved-car-t-cell-therapies-for-hematologic-malignancies-in-2025/ 2026-01-11T23:51:58+08:00 https://cartcellschina.com/multiple-myeloma-patient-traveled-from-the-uk-to-china-for-car-t-cell-therapy/ 2026-01-01T10:13:24+08:00 https://cartcellschina.com/tim-sharing-his-experience-of-getting-car-t-cell-therapy-in-china-for-multiple-myeloma/ 2025-12-24T11:35:49+08:00 https://cartcellschina.com/real-world-evidence-yorwida-car-t-therapy-improves-outcomes-in-adult-b-all-with-high-risk-genetics/ 2025-12-14T19:39:10+08:00 https://cartcellschina.com/car-t-therapy-brings-new-hope-for-rare-lymphoma-complicated-with-autoimmune-disease/ 2025-11-30T20:52:05+08:00 https://cartcellschina.com/fully-human-gprc5d-car-t-cell-therapy-shows-durable-remission-in-relapsed-refractory-multiple-myeloma/ 2025-11-13T00:31:28+08:00 https://cartcellschina.com/largest-real-world-study-shows-car-t-therapy-achieves-durable-remission-in-primary-central-nervous-system-lymphoma-pcnsl/ 2025-11-13T00:29:47+08:00 https://cartcellschina.com/cd22-car-t-therapy-for-relapsed-b-all-after-cd19-directed-immunotherapy/ 2025-11-13T00:25:33+08:00 https://cartcellschina.com/case-report-complete-remission-lasting-over-2-years-after-car-t-treatment-in-a-high-risk-mantle-cell-lymphoma-patient/ 2025-09-21T10:35:11+08:00 https://cartcellschina.com/carteyva-china-made-car-t-cell-immunotherapy-brings-new-hope-of-cure-for-patients-with-relapsed-refractory-lymphoma/ 2025-09-14T00:28:10+08:00 https://cartcellschina.com/battling-mantle-cell-lymphoma-with-carteyva-car-t-therapy-after-chemo-and-targeted-drugs-failed/ 2025-09-03T20:54:16+08:00 https://cartcellschina.com/beyond-cancer-and-autoimmune-diseases-what-other-diseases-can-car-t-treat-in-the-future/ 2025-09-01T23:21:39+08:00 https://cartcellschina.com/car-t-therapy-finds-new-target-cd22-car-t-achieves-68-orr-in-r-r-lbcl/ 2025-08-26T22:19:49+08:00 https://cartcellschina.com/the-lancet-chinese-car-t-trial-extends-cancer-patients-survival-by-40/ 2025-08-26T21:56:31+08:00 https://cartcellschina.com/allogeneic-cd19-targeted-car-t-cells-achieve-durable-remission-in-refractory-systemic-lupus-erythematosus/ 2025-08-26T21:35:18+08:00 https://cartcellschina.com/understanding-in-vivo-car-t-cell-therapy-a-new-frontier-in-cancer-treatment/ 2025-08-13T23:33:36+08:00 https://cartcellschina.com/an-update-on-the-experience-with-car-t-cell-therapy-in-china/ 2025-08-12T20:33:55+08:00 https://cartcellschina.com/chinese-scientist-honored-by-nature-for-pioneering-universal-car-t-therapy-in-autoimmune-diseases/ 2025-08-12T20:31:49+08:00 https://cartcellschina.com/world-first-breakthrough-off-the-shelf-car-t-therapy-shows-promise-for-autoimmune-diseases/ 2025-08-12T20:31:41+08:00 https://cartcellschina.com/hicara-chinas-home-grown-cd19-car-t-cell-therapy-approved-for-lymphoma/ 2025-07-31T22:21:08+08:00 https://cartcellschina.com/which-car-t-cell-therapies-are-approved-in-china/ 2025-07-29T21:41:24+08:00 https://cartcellschina.com/carteyva-relma-cel-car-t-cell-therapy-offers-new-hope-for-elderly-patients-with-relapsed-refractory-dlbcl/ 2025-07-20T15:27:32+08:00 https://cartcellschina.com/car-t-cell-therapy-brings-new-hope-for-autoimmune-disease-treatment/ 2025-07-13T21:02:56+08:00 https://cartcellschina.com/breakthrough-in-car-t-therapy-for-liver-cancer-first-patient-survives-nearly-5-years-cancer-free/ 2025-07-13T20:29:39+08:00 https://cartcellschina.com/dual-target-car-t-cell-therapy-shows-promise-in-slowing-aggressive-brain-tumors/ 2025-07-13T18:48:14+08:00 https://cartcellschina.com/what-cancers-can-be-treated-with-car-t-cell-therapy/ 2025-07-13T18:33:50+08:00 https://cartcellschina.com/what-are-the-tumor-markers-in-blood-cancers-for-car-t-cell-therapy/ 2025-07-13T18:33:24+08:00 https://cartcellschina.com/why-are-tumor-markers-important-in-car-t-cell-therapy/ 2025-07-13T18:33:17+08:00 https://cartcellschina.com/what-are-tumor-markers-why-are-they-important-in-cancer-treatment/ 2025-07-13T18:33:11+08:00 https://cartcellschina.com/how-does-car-t-cell-therapy-find-cancer/ 2025-07-13T18:33:05+08:00 https://cartcellschina.com/what-are-t-cells-how-important-are-they/ 2025-07-13T18:32:59+08:00 https://cartcellschina.com/what-are-the-differences-between-car-t-cell-therapy-and-other-cancer-therapies/ 2025-07-13T18:32:51+08:00 https://cartcellschina.com/who-can-have-car-t-cell-therapy/ 2025-07-13T18:32:41+08:00 https://cartcellschina.com/what-is-chimeric-antigen-receptor-t-cell-therapy/ 2025-07-13T18:32:36+08:00 https://cartcellschina.com/fucaso-for-multiple-myeloma-car-t-therapy-testimonial-thanyaphat/ 2025-04-19T23:42:24+08:00 https://cartcellschina.com/the-prospects-of-car-t-therapy-in-autoimmune-rheumatic-diseases/ 2024-12-27T22:15:40+08:00 https://cartcellschina.com/mrs-qins-journey-to-recovery-5-years-after-yescarta-car-t-cell-therapy/ 2024-12-22T17:41:08+08:00